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Abstract
Background Optimising techniques to wean patients from invasive mechanical ventilation (IMV) remains a key goal of inten-
sive care practice. The use of non-invasive ventilation (NIV) as a weaning strategy (transitioning patients who are difficult 
to wean to early NIV) may reduce mortality, ventilator-associated pneumonia and intensive care unit (ICU) length of stay.
Objectives Our objectives were to determine the cost effectiveness of protocolised weaning, including early extubation onto 
NIV, compared with weaning without NIV in a UK National Health Service setting.
Methods We conducted an economic evaluation alongside a multicentre randomised controlled trial. Patients were ran-
domised to either protocol-directed weaning from mechanical ventilation or ongoing IMV with daily spontaneous breathing 
trials. The primary efficacy outcome was time to liberation from ventilation. Bivariate regression of costs and quality-adjusted 
life-years (QALYs) provided estimates of the incremental cost per QALY and incremental net monetary benefit (INMB) 
overall and for subgroups [presence/absence of chronic obstructive pulmonary disease (COPD) and operative status]. Long-
term cost effectiveness was determined through extrapolation of survival curves using flexible parametric modelling.
Results NIV was associated with a mean INMB of £620 ($US885) (cost-effectiveness threshold of £20,000 per QALY) 
with a corresponding probability of 58% that NIV is cost effective. The probability that NIV is cost effective was higher 
for those with COPD (84%). NIV was cost effective over 5 years, with an estimated incremental cost-effectiveness ratio of 
£4618 ($US6594 per QALY gained).
Conclusions The probability of NIV being cost effective relative to weaning without NIV ranged between 57 and 59% overall 
and between 82 and 87% for the COPD subgroup.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-020-00210 -1) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Optimising techniques to wean patients from invasive 
mechanical ventilation (IMV) remains a key goal of inten-
sive care practice [1, 2]. To date, no definitive guidelines 
exist on the best approach to use in the intensive care unit 
(ICU) [2]. Evidence from structured and systematic and 
literature reviews of studies, including randomised con-
trolled trials (RCTs) suggests that the use of non-inva-
sive ventilation (NIV) as a weaning strategy (transition-
ing patients who are difficult to wean to early NIV) may 
reduce mortality, ventilator-associated pneumonia and 
ICU length of stay, although this beneficial effect may be 
limited to patients with chronic obstructive pulmonary 
disease (COPD) [3, 4, 8].
 I. Khan et al.
Key Points for Decision Makers 
Early extubation to non-invasive ventilation (NIV) did 
not shorten time to liberation from ventilation.
However, the probability of NIV being cost effective  
relative to weaning without NIV was modest: 
between 57% and 59%.
For patients with chronic obstructive pulmonary dis-
order, the probability of cost effectiveness of NIV was 
much higher (82–87%).
Future trials with extended follow-up are needed to 
reduce uncertainty surrounding the long-term cost effec-
tiveness of NIV.
breathing trial (SBT). Patients were randomised to receive 
either protocolised weaning with extubation to NIV (non-
invasive weaning) or protocolised weaning via IMV with 
daily SBTs (invasive weaning). NIV refers to the delivery 
of mechanical ventilation without the need for an endotra-
cheal airway. Positive pressure ventilation is delivered to the 
patient through the mouth or nose via an interface such as 
a mask or helmet.
Clinicians were permitted to use one of three types of 
SBT in accordance with local unit practices: a T-piece 
trial, use of continuous positive airway pressure (CPAP) 
or low-level pressure support (5–7 cm  H2O). A T-piece 
trial involves the patient breathing spontaneously through 
their endotracheal tube, with the appropriate inspired oxy-
gen concentration being maintained by a cross-flow device 
(T-piece). CPAP involved leaving a standing pressure of 
5–10 cm  H2O delivered via the ventilator at the top of the 
endotracheal tube but with no assistance on inspiration. 
A low-level pressure support trial provided 5–7 cm  H2O 
inspiratory assistance.
Each SBT was scheduled to last for at least 30 min and 
could be increased up to 120 min in patients considered to 
be at higher risk of re-intubation (e.g. prolonged ventilation, 
past history of COPD, heart failure). During SBTs, patients 
were closely monitored for the following signs of distress or 
fatigue: heart rate > 20% of baseline or > 140 beats  min−1; 
systolic blood pressure > 20% of baseline or > 180 mmHg 
or < 90 mmHg; cardiac arrhythmias; respiratory rate > 50% 
of baseline value or > 35 min−1, respiratory rate (min)/tidal 
volume (L) > 105 min−1 L−1; arterial blood gases; clinical 
assessments such as agitation, anxiety or depression. A 
patient was considered to pass the SBT if no signs of distress 
or fatigue developed. A patient who displayed any sign of 
distress or fatigue was judged to have failed the SBT.
Clinicians were provided with information about the 
Walsh criteria, which were suggested as guidance to indi-
cate when the patient was ready to commence weaning [9]. 
The Walsh criteria recommend that meeting all the follow-
ing conditions indicates readiness for weaning: cooperative 
and pain free; good cough;  PaO2:FiO2 (ratio of arterial oxy-
gen partial pressure to fractional inspired oxygen) > 24 kPa; 
positive end-expiratory pressure < 10 cm  H2O; haemoglo-
bin > 7 g  dL−1; axillary temperature 36–38.5 °C; vasoactive 
drugs reduced or unchanged over previous 24 h; and sponta-
neous ventilatory frequency > 6 breaths per minute. Heated 
humidified oxygen (on both invasive ventilation and NIV) 
was not mandated or recommended in the study protocol 
but could be used at clinician discretion in accordance with 
local unit policy.
A sample size of 364 (90% power, two-sided 5% type 
I error), allowing for a 23% dropout rate, was required to 
detect a clinically meaningful median difference of 24 h 
In light of current clinical practices [2], the findings 
of existing trials are of limited generalizability to clini-
cal settings across a number of industrialised countries as 
treatment pathways for COPD exacerbations vary across 
settings and over time. Whereas patients with respiratory 
failure would have previously received IMV, in the UK for 
example, this is now largely reserved for patients who fail 
a trial of NIV. Furthermore, few published studies have 
reported the impact of NIV on health-related quality of life 
(HRQoL) outcomes [3] or economic costs associated with 
NIV in critical care settings [5, 6]. Where these have been 
reported, sample sizes are small [6] or focus has solely 
been on patients with an exacerbation of COPD. Impor-
tantly, only one study, conducted in Canada, has estimated 
the cost effectiveness of NIV as a weaning strategy in 
patients with COPD [7], whereas, to our knowledge, no 
study has estimated its cost effectiveness in patients within 
the ICU presenting with or without COPD.
It is crucial to evaluate the cost effectiveness of NIV 
before its use can be considered more widely. We therefore 
present a health economic evaluation from a multicentre 
RCT comparing protocolised weaning that includes early 
extubation onto NIV versus weaning without NIV (Breathe 
study; ISRCTN 15,635,197).
2  Materials and Methods
2.1  Trial Background
Details of the design and clinical outcome measures for the 
Breathe study are reported elsewhere [8]. Briefly, patients 
aged ≥ 16 years recruited from 41 UK critical care units 
were eligible for randomisation if they had received IMV for 
over 48 h, were ready to wean and had failed a spontaneous 
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between the non-invasive and invasive group for the primary 
outcome of time to liberation from ventilation.
2.2  Study Perspective and Time Horizon
The primary economic analysis was undertaken from the 
perspective of the UK National Health Service (NHS) and 
personal social services (PSS) [10]. The time horizon for the 
within-trial economic evaluation was limited to a follow-up 
period of 6 months. In addition, a 5-year time horizon was 
considered for a long-term cost-effectiveness analysis. A 
discount rate of 3.5% per annum was applied to both costs 
and effects during years 2–5 for the longer-term cost-effec-
tiveness analysis [10].
2.3  Measurement and Valuation of Resource Use
Resource use data were collected from randomisation to 
6 months post-randomisation using case report forms (for 
initial hospitalisations) and participant questionnaires. The 
resource and cost components associated with the interven-
tion were aggregated into five groups:
1. intensive care support, including organ support, level of 
care and use of sedatives,
2. tracheostomies,
3. use of high-cost antivirals and antifungals or other high-
cost drugs in the ICU,
4. hospital care between ICU discharge and hospital dis-
charge,
5. use of any emergency transport to transfer patients 
between hospital sites.
For critical care stays, healthcare resource groups (HRGs) 
were assigned according to the maximum number of organ 
systems supported daily during each stay. Critical care 
HRGs value standard resource expenditures (e.g. staffing, 
consumables, diagnostics), such that high-cost drugs and 
interventions were separately collected and valued to derive 
a total overall critical care cost. Following critical care dis-
charge, the costs of step-down care were based on number 
of days spent in each step-downward/facility (until death 
or discharge) multiplied by the respective per diem cost for 
that level of care [11]. Further details of healthcare resource 
use can be found in Table 1 in the electronic supplementary 
material (ESM) and include the number of organs supported, 
the number of days in ICU, highest level of care and details 
of tracheostomies, antifungal/antiviral use, inpatient and out-
patient care, residential care services, community health and 
social care, frequency of prescription medications, equip-
ment and aids and additional health resource used by patient 
or carer/supporter.
Differences in resource use between the two intervention 
groups for the period between randomisation and hospital 
discharge were determined by (1) comparing the number of 
days that patients had two or more organs supported while in 
the ICU (or alternatively, days in level 3 care); (2) compar-
ing differences in overall length of stay in the ICU; and (3) 
comparing proportions of patients who required tracheosto-
mies, used high-cost antifungals, used high-cost antivirals or 
needed emergency transport for transfers between hospitals. 
Patients requiring support for two or more organs and those 
receiving advanced respiratory support alone were consid-
ered to receive level 3 care [12].
Broader health and PSS resource use data (e.g. hospital 
readmissions, contacts with community health and social 
care professionals, medication use) were collected at 3 and 
6 months post-randomisation using postal questionnaires 
completed by participants or their primary carers. We also 
collected data on direct non-medical costs (including travel 
expenses) incurred by patients and their caregivers, days off 
work and loss of earnings. Resource use values were con-
verted into costs by applying unit costs obtained from key 
UK national databases [13–20] (Table 2 in the ESM).
All costs were expressed in £ sterling (year 2015–2016 
values). Where appropriate, costs were inflated to year 
2015–2016 values using the NHS Hospital and Community 
Health Services Pay and Prices index [21].
2.4  Measurement and Valuation of Health 
Outcomes
The primary outcome for the economic evaluation was 
the quality-adjusted life-year (QALY) [10]. HRQoL was 
assessed using the three-level EuroQol 5-Dimensions (EQ-
5D-3L) [22] at 3 and 6 months post-randomisation. The 
EQ-5D-3L descriptive system consists of five dimensions 
(mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression), each divided into three ordinal levels: 
(1) no problems, (2) some or moderate problems, and (3) 
severe or extreme problems. The UK time trade-off tariff 
was applied to each set of responses to generate an EQ-
5D-3L utility score for each participant [23]. Given the chal-
lenges of collecting baseline data from patients in critical 
care settings, we assumed in the baseline analysis that the 
baseline utility value was − 0.402, the value assigned by the 
EQ-5D-3L tariff to an unconscious health state [24]. QALY 
values for each patient were calculated as the area under the 
baseline-adjusted utility curve [25] assuming a fixed base-
line of − 0.402 (equivalent to an unconscious health state) 
and using linear interpolation between baseline and follow-
up utility scores. QALYs were also derived from 6-Dimen-
sion Short-Form survey (SF-6D) utilities (UK tariff), gen-
erated from responses to the SF-12 as a sensitivity analysis 
[26], assuming a baseline utility value of zero. Patients who 
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Table 1  Economic costs for complete cases for entire follow-up period, by trial allocation and cost category (£; year 2015–16 values)
Evaluation period by cost type Non-invasivea Invasivea Mean difference p value Bootstrap 95% CI
Randomisation to hospital discharge n = 182 n = 182
 Intensive care  supportb 20,509.7 ± 1762.56 22,018.9 ± 1685.17  − 1509.2 0.5515  − 5533.9 to 2586.3
 Tracheostomy 980.9 ± 131.08 1254.6 ± 141.7  − 273.7 0.1570  − 584.1 to 57.2
 Antivirals/antifungals 455.7 ± 194.91 758.2 ± 219.66  − 302.5 0.3036  − 768.1 to 215.8
 Hospital care between ICU and hospital discharge 7694.5 ± 695.69 7967.0 ± 1038.27  − 272.5 0.8275  − 2511.2 to 1682.5
 Transfer by ambulance/NHS transport 56.0 ± 7.97 53.1 ± 7.82 2.87 0.7971  − 16.1 to 20.7
 Total NHS and PSS costs 29,696.8 ± 2069.8 32,051.8 ± 2204.56  − 2355.0 0.4472  − 7291.5 to 2750.0
Hospital discharge to 3 months post − randomisa-
tion
n = 130 n = 131
 Health and social care resource use
  Hospital inpatient care 686.8 ± 163.83 381.8 ± 123.63 305.0 0.1387  − 30.0 to 642.2
  Hospital outpatient care 130.7 ± 25.95 86.7 ± 17.41  − 4.0 0.1602  − 5.2 to 97.3
  Residential care 158.6 ± 55.55 43.2 ± 22.64 115.4 0.0560 20.1 to 219.7
  Community health and social care 280.7 ± 46.03 301.3 ± 75.31  − 20.6 0.8157  − 171.3 to 114.3
  Medications 67.8 ± 21.23 139.5 ± 36.84  − 71.7 0.0935  − 141.4 to − 4.7
  Equipment and aids 32.2 ± 8.79 13.9 ± 4.71 18.3 0.0679 2.8 to 35.5
 Total NHS and PSS costs 1356.8 ± 196.32 966.4 ± 151.99 390.4 0.0836  − 47.1 to 775.7
 Broader societal costs
  Additionalc 108.6 ± 33.02 297.7 ± 129.15  − 189.1 0.0926  − 324.6 to − 4.2
  Equipment and aids (private and charity) 29.3 ± 10.53 158.3 ± 120.1  − 129 0.2854  − 259.3 to 131.4
    Total broader societal costs 137.9 ± 22.47 456.0 ± 93.68  − 318.1 0.0012  − 434.1 to − 158.4
      Total societal costs 1104.3 ± 179.61 1812.8 ± 202.29  − 708.5 0.0004  − 1108.2 to − 308.4
3 months post-randomisation to 6 months post-
randomisation
n = 129 n = 127
 Health and social care resource use
  Hospital inpatient care 788.4 ± 203.12 403.0 ± 144.18 385.4 0.1233  − 7.0 to 1101.3
  Hospital outpatient care 131.5 ± 20.23 123.0 ± 24.85 28.50 0.7913  − 56.8 to 105.0
  Residential care 264.4 ± 140.96 0.0 ± 0.00 264.0 0.0630 57.6 to 515.2
  Community health and social care 373.2 ± 102.74 214.5 ± 66.54 158.7 0.1963  − 33.2 to 362.5
  Medications 176.2 ± 45.39 206.0 ± 46.65  − 29.8 0.6480  − 135.9 to 78.5
  Equipment and aids 30.9 ± 6.30 17.4 ± 5.25  − 13.5 0.1010  − 0.27 to 26.9
 Total NHS and PSS costs 1764.6 ± 258.47 963.9 ± 157.71 798.6 0.0031 308.9 to 1294.7
 Broader societal costs
  Additionalc 171.8 ± 70.17 245.9 ± 110.38  − 74.1 0.3864  − 207.6 to 52.9
  Equipment and aids (private and charity) 25.9 ± 9.67 14.7 ± 12.5 11.2 0.4788  − 10.8 to 33.2
  Total broader societal costs 197.7 ± 45.3 260.6 ± 66.3  − 62.9 0.4336  − 173.9 to 48.1
  Total societal costs 1962.3 ± 265.94 1224.5 ± 178.96 737.8 0.2262  − 432.6 to 1928.3
 From randomisation to 6 months post-randomi-
sation
n = 129 n = 127
 Initial hospitalisation costs
  Intensive care  supportb 20,815.7 ± 2,134,027 21,659.9 ± 2059.30  − 844.2 0.7761  − 5699 to 4114
  Tracheostomy 922.6 ± 149.01 1129.5 ± 159.01  − 206.9 0.3435  − 570.1 to 151.2
  Antivirals/antifungals 448.2 ± 234.98 968.8 ± 288.76  − 520.6 0.1635  − 1131.2 to 89.9
  Hospital care between ICU and hospital dis-
charge
6613.3 ± 707.09 6914.7 ± 896.01  − 301.4 0.7921  − 2229 to 1519
  Transfer by ambulance/NHS transport 42.6 ± 8.33 46.1 ± 8.57  − 3.5 0.7681  − 23.3 to 16.1
 Total NHS and PSS costs 28,842.4 ± 2462.57 30,719.0 ± 2501.67  − 1876.6 0.5934  − 7612 to 3989
 Health and social care resource use
  Hospital inpatient care 1323.6 ± 294.88 698.2 ± 221.55 625.4 0.0913 28.3 to 1236.9
  Hospital outpatient care 240.7 ± 39.10 188.8 ± 34.85 51.9 0.3222  − 33.4 to 139.6
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survived the initial hospital admission were also asked to 
recollect their pre-admission health state using both the EQ-
5D-3L and the SF-12 questionnaires.
2.5  Missing Data
Multiple imputation under chained equations [27] was used 
for missing resource use or HRQoL data, based on the tested 
assumption that data were missing at random. Regression 
models were used to estimate missing costs and QALYs at 
each time point, by treatment allocation, conditional on fully 
observed baseline variables: age, sex, randomisation centre, 
presence/absence of COPD, non-operative/operative status 
and post-SBT  PaCO2. In total, 20 datasets were generated 
using predictive mean matching. Estimates obtained were 
pooled to generate mean and variance estimates for costs and 
QALYs in each allocation group over the trial time horizon 
using Rubin’s rule [28]. All mean incremental costs take into 
account heterogeneity in baseline costs, leading to estimates 
of incremental costs that would have adjusted for costs aris-
ing from differences between groups in terms of severity at 
baseline [8].
2.6  Analyses of Resource Use, Costs and Outcome 
Data
Economic values were summarised by treatment group, 
resource category and assessment time; differences between 
groups were analysed using two-sample t tests. Non-para-
metric bootstrapping, based on 10,000 replications (10,000 
was expected to stabilise the confidence intervals [CIs] for 
point estimates), was used to assess whether differences in 
mean total costs between allocation groups were statistically 
significant. EQ-5D-3L utility scores were compared using 
two-sample t tests.
2.7  Cost‑Effectiveness Analysis
A cost-effectiveness analysis using individual patient-
level data was conducted. Cost-effectiveness results were 
expressed in terms of an incremental cost-effectiveness ratio 
(ICER) and calculated by dividing the difference between 
trial arms in mean total costs by the difference in mean 
total QALYs. Value-for-money assessments involved com-
paring the ICER value with a range of cost-effectiveness 
thresholds. Cost-effectiveness thresholds held by UK deci-
sion makers typically range between £20,000 and 30,000 
per QALY [10].
Several types of uncertainty analyses were undertaken. 
Stochastic uncertainty was presented in terms of CIs, deci-
sion uncertainty was undertaken using various cost-effec-
tiveness thresholds that determined the INMB, and uncer-
tainty from heterogeneity was implicitly assessed through 
modelling the pre-specified covariates (presence/absence 
of COPD, operative status, baseline costs, baseline utility) 
considered to be related to cost-effectiveness outcomes. In 
addition, 10,000 estimates of incremental costs and ben-
efits were generated through non-parametric bootstrapping 
to determine the level of sampling uncertainty around the 
ICER. The bootstrap replicates were used to populate cost-
effectiveness scatterplots. We also calculated the incremen-
tal net monetary benefit (INMB) of using NIV versus IMV 
across three cost-effectiveness thresholds: £15,000 [29], 
£20,000 and £30,000 per QALY gained. A positive INMB 
Table 1  (continued)
Evaluation period by cost type Non-invasivea Invasivea Mean difference p value Bootstrap 95% CI
  Residential care 405.4 ± 150.44 41.6 ± 21.81 363.8 0.0180 132.7 to 632.6
  Community health and social care 613.8 ± 129.40 475.5 ± 124.74 138.3 0.4426  − 153.7 to 424.5
  Medications 226.3 ± 59.99 315.8 ± 68.56  − 89.5 0.3268  − 237.9 to 60.7
  Equipment and aids 59.1 ± 10.89 28.6 ± 8.45 30.5 0.0276 7.3 to 53.4
 Total NHS and PSS costs 2868.9 ± 392.94 1748.5 ± 276.45 1120.4 0.0494 176.5 to 1542.9
 Broader societal costs
  Additionalb 171.7 ± 67.65 374.6 ± 164.09  − 202.9 0.2542  − 441.1 to − 23.3
  Equipment and aids (private and charity) 51.2 ± 24.45 157.0 ± 98.87  − 105.8 0.2498  − 179.3 to 16.0
Total broader societal costs 222.9 ± 97.44 531.6 ± 120.33  − 309.7 0.0142  − 489.5 to 272.6
Total societal costs 3091.8 ± 392.94 2280.1 ± 276.45 811.7 0.3163  − 128.3 to 1371.6
Total NHS/PSS including ICU 31,711.3 ± 2498.47 32,467.5 ± 2550.99  − 756.2 0.8321  − 6642.1 to 5245.7
Total societal including ICU 31,934.2 ± 2498.58 32,999.1 ± 2547.95  − 1064.9 0.7981  − 6804.2 to 5055.9
CI confidence interval, ICU intensive care unit, NHS national health service, PSS Personal and Social Services
a Data are presented as mean ± standard error of the mean
b Includes organ monitoring support, level of care and antibiotics
c Includes travel, childcare, income lost, housework help and laundry services costs
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indicates that the intervention is cost effective compared 
with the alternative at the given cost-effectiveness thresh-
old. Cost-effectiveness acceptability curves (CEACs) sum-
marised the likelihood that NIV was cost effective as the 
cost-effectiveness threshold varies.
2.7.1  Sensitivity and subgroup analyses
Sensitivity analyses included (1) adopting a wider soci-
etal perspective encompassing direct non-medical costs 
incurred by trial participants and their families, and eco-
nomic values placed on attributable work absences being 
collected in the case report form by asking patients/carers 
whether items such as travel cost and income lost occurred 
and how much cost was incurred; (2) restricting analysis to 
complete cases; (3) using SF-6D utility scores estimated 
from the SF-12 for the purposes of QALY estimation; and 
(4) additionally using the pre-randomisation EQ-5D-3L 
utility value (recalled at hospital discharge) as a covari-
ate for the purpose of QALY adjustments. Pre-specified 
subgroup analyses were presence/absence of COPD and 
operative status.
2.8  Longer‑Term Economic Modelling
2.8.1  Extrapolation of Survival Data
Long-term cost effectiveness was determined over a 5-year 
time horizon by extrapolating survival beyond 6 months. 
The 5-year point was arbitrary; but we felt that extrapolating 
beyond 5 years would have generated too much uncertainty. 
For a cost-effectiveness analysis conducted over a lifetime 
horizon, using data from many patients who were censored 
would potentially lead to highly uncertain survival rates. 
Observed survival curves (Fig. 1 in the ESM) showed that 
most deaths occurred between randomisation and hospital 
discharge; a 5-year time horizon therefore limited the uncer-
tainty of the long-term cost-effectiveness results compared 
with modelling over a lifetime horizon.
A flexible parametric model was used to predict survival 
rates at each time point [30]. Flexible parametric models are 
commonly used in the assessment of the cost effectiveness of 
cancer drugs for prediction of survival beyond trial follow-
up [31]. Three parametric models were considered: exponen-
tial, Weibull and a more flexible model using cubic splines 
with up to four knots (points at which splines are joined). 
This involved fitting survival curves using the observed sur-
vival data by modelling the background (baseline hazard) 
risk of death over time and the risk of death due to interven-
tion. The choice of model selection was based on Akaike’s 
information criterion (AIC). The parameter estimates and 
corresponding standard errors were reported. The observed 
survival data (time to death) were used along with a censor-
ing variable, and stratified covariates were included in the 
model.
2.8.2  Extrapolation of Costs and Quality‑Adjusted 
Life‑Years (QALYs)
We adopted a conservative approach to estimating (extrapo-
lated) longer-term costs and health utilities beyond 6 months 
separately for each treatment group. Costs between 6 months 
and 5 years post-randomisation were estimated by using the 
observed 3- to 6-month post-randomisation total costs but 
also adjusting for covariates and multiplying by the pre-
dicted survival probabilities over the 5-year post-randomi-
sation period. The trial-based estimates of health utilities 
(adjusted for covariates) were used as a basis for estimating 
utility values beyond 6 months.
The primary assumption for longer-term cost effec-
tiveness was that future costs and utility patterns beyond 
6 months were equal, so only predicted survival rates were 
likely to drive future costs and QALYs. Thereafter, several 
sensitivity analyses were undertaken for how future cost and 
utility patterns could behave, including (1) the 6-month util-
ity values were carried forward (linear constancy); (2) utili-
ties declined in a linear fashion; (3) utilities declined expo-
nentially; (4) survival rates were lower in the NIV arm by 
10% (justified by an examination of the plots of log-survival 
and hazard function); (5) future costs and utilities differed 
between arms based on 6-month values (carried forward); 
and (6) future costs were assumed equal but future utilities 
could differ. The estimated utility values in each of these 
alternative scenarios (adjusted for proportion of patients 
alive at the corresponding time point) were used to compute 
the 5-year QALY estimates. A further sensitivity analysis of 
longer-term cost-effectiveness outcomes adopted a societal 
perspective.
All statistical and cost-effectiveness analyses were under-
taken using  SAS® version 9.4 on a Windows platform. A pub-
lished SAS macro [31] was used for flexible parametric model-
ling. Reporting was made in line with the CHEERS statement 
[32]. The trial protocol was designed by the trial investigators 
and was approved by South Central C Research Ethics Com-
mittee (reference 12/SC/0515).
3  Results
Details of the clinical study have been reported elsewhere 
[8]. Briefly, 364 patients were randomised: 182 to non-
invasive weaning and 182 to invasive weaning. The pri-
mary clinical endpoint showed no clinical or statistical 
difference in median time to liberation from mechanical 
ventilation: median 4.3 vs. 4.5 days; adjusted hazard ratio 
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1.1; 95% CI 0.89–1.40. Early extubation to NIV did not 
shorten time to liberation from any ventilation. Approxi-
mately 52 and 50% of all health resource use data were 
complete at 3 months for the non-invasive and invasive 
groups, respectively; this was 51 and 46%, respectively, at 
6 months (Table 3 in the ESM).
A complete QALY profile was available for about 50% of 
patients (179/364) (Table 3 in the ESM). Data were missing 
because patients either died before 3 months (n = 82), were 
not available to provide a response (n = 60) or withdrew from 
follow-up (n = 37).
3.1  Resource Use and Economic Costs
Resource use for the period between randomisation and hos-
pital discharge was generally higher for patients allocated to 
the invasive group (Table 1 in the ESM). The proportion of 
patients who used antifungals was significantly higher in the 
invasive group (12% for IMV vs. 5% for NIV; p = 0.0168). 
Broader resource use (post-initial hospital discharge) was 
similar between the non-invasive and invasive groups.
The mean intervention costs from randomisation until 
hospital discharge were £29,697 and 32,052 for NIV and 
IMV participants with complete data, respectively: mean 
cost difference − £2355; 95% CI – 7292 to 2750; p = 0.4472 
(Table 1).
The mean total NHS and PSS costs throughout the first 
6 months post-randomisation were, on average, lower for 
the non-invasive group than for the invasive group: £31,711 
versus 32,468; mean difference − 756.20; 95% CI – 6642 
to 5246; p = 0.8321 (Table 1). Mean societal costs were 
£31,934 and 32,999, respectively; mean difference − 1065; 
95% CI – 6804 to 5056; p = 0.7981. The wide CIs for dif-
ferences in mean costs reflected the uncertainty in the esti-
mates. Significant differences between groups in terms of 
baseline clinical characteristics were not observed.
3.2  Health‑Related Quality‑of‑Life Outcomes 
and QALYs
There were no significant differences in EQ-5D-3L out-
comes between the trial groups prior to hospital admission 
or at 3 months post-randomisation (Tables 4 and 5 in the 
ESM).
However, mean EQ-5D-3L utility scores among complete 
cases were significantly lower at 6 months post-randomisa-
tion for the NIV group (0.53 vs. 0.66; p = 0.0147). The mean 
QALY value was, on average, higher for the NIV group 
(0.0928 vs. 0.0747; p = 0.4522). The mean improvement in 
QALYs was because mean utility at a specific time point 
was based on observed cases and did not consider deaths 
(utility score of 0) and differential survival rates. Since more 
patients died in the invasive group, more utility scores were 
set to zero. Moreover, our QALY estimates are derivations 
over time, based on modelled estimates of mean utility at 
each time point, taking into account heterogeneity and miss-
ing data.
3.3  Cost‑Effectiveness Analysis
The base-case economic evaluation, using imputed attribut-
able costs and QALYs and covariate adjustment, indicated 
that—over the first 6 months—NIV was associated with a 
lower net cost (− £302; 95% CI – 5490 to 4760) and a higher 
net effect (0.02 QALYs; 95% CI − 0.01 to 0.05) and was 
therefore dominant (Table 2).
The simulated ICERs showed uncertainty largely across 
the north-east and south-east quadrants of the cost-effective-
ness plane (Fig. 1).
The NIV protocol showed net economic gains based 
on INMBs of £541, £620 and £779, on average, at cost-
effectiveness thresholds of £15,000, £20,000 and £30,000 
per QALY, respectively (Table 2). The CEAC shows that 
the probability that NIV is cost effective is approximately 
57–59% across cost-effectiveness thresholds (Fig. 1). INMBs 
were similar across scenarios considered by the sensitivity 
analyses, indicating that the results are robust to alternative 
assumptions (Fig. 2; Figs. 2 and 3 in the ESM).
3.3.1  Subgroup Analyses
Both presence of COPD and operative status had a notable 
impact on cost-effectiveness results (Fig. 2; Figs. 2 and 3 in 
the ESM). For patients with COPD, the probability that NIV 
is cost effective increased to 82–87% (Table 2). In contrast, 
the probability of cost effectiveness was < 30% among post-
operative surgical patients. A tornado diagram displaying 
the impact on the INMB of variations in several inputs is 
provided in Fig. 5 in the ESM.
3.4  Results of Longer‑Term Cost‑Effectiveness 
Analysis
The base-case extrapolation analysis, based on mortality 
predictions using the Royston–Parmar model [3 knots; i.e. 
a RP(4) model] yielded mean survival times (over the 5-year 
time horizon) of 41.9 versus 33.3 months for the non-inva-
sive versus the invasive group, respectively. Among the three 
models [exponential, Weibull and RP(4)] used to predict 
survival rates to 5 years (Table 7 and Fig. 1 in the ESM), 
the RP(4) model showed the smallest AIC value (a well-
established metric of model fit). Extrapolated survival rate 
estimates were in broad agreement with those in published 
studies [33–35], which report 1-, 2- and 3-year survival 
rates of 69%, 50% and 47%, respectively. For the invasive 
group, these were 65%, 60% and 50% at years 1, 2 and 3, 
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respectively. There was no statistically significant difference 
between the two survival curves for survival data observed 
during the trial (log rank p value = 0.366). The above models 
also confirmed this (Table 6 in the ESM).
The extrapolated survival to 5 years post-randomisation 
estimated that 67% of patients were expected to remain alive 
in the non-invasive group versus 45% for the invasive group. 
However, given the high uncertainty around these estimates 
as a result of extrapolation, we also conducted sensitivity 
analyses (Table 8 in the ESM) that included an assumption 
of equal future (beyond 6 months and 5 years) survival rates 
between arms.
Under the assumption that future costs and utility patterns 
beyond 6 months are equal (based on extrapolated survival 
data), the mean discounted expected QALYs were 2.25 (non-
invasive group) and 1.82 (invasive group) (Table 7 in the 
ESM), resulting in an incremental QALY gain of 0.427. The 
mean NHS and PSS costs over the entire 5-year period were 
higher in the NIV group than in the IMV group (£43,759 
vs. 41,787, respectively). The 5-year ICER associated with 
NIV was £4618 per QALY gained (an INMB of £10,838 at 
Fig. 1  a Cost-effectiveness 
plane, b cost-effectiveness 
acceptability curve for base 
case: fixed baseline utility, 
imputed costs, adjustment for 
covariates
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a cost-effectiveness threshold of £30,000). The probability 
that NIV was cost effective was > 90% at a cost-effectiveness 
threshold of £20,000 per QALY (Fig. 7 in the ESM).
However, the sensitivity analyses indicated that the prob-
ability of cost effectiveness for NIV strongly depended on 
assumptions surrounding future costs, utilities and survival 
rates beyond 6 months (Table 8 and Figs. 4 and 6 [tor-
nado plot] in the ESM). In particular, under the assump-
tion of equal survival rates between 6 months and 5 years, 
and equal future utilities, the mean incremental costs and 
QALYs were (non-invasive vs. invasive group) £6453 and 
− 0.092 (Table 8 in the ESM), respectively, yielding nega-
tive INMBs ranging between £7833 and £9213 favouring 
invasive weaning. This showed that the incremental QALY 
gains in favour of NIV were largely driven by the higher 
extrapolated survival rates for the NIV arm. Hence, despite 
predicted survival rate estimates being in broad agreement 
with those in published studies [33–35], the uncertainty 
around the long-term cost-effectiveness results should be 
carefully considered.
When the projected survival rates were assumed to be 
lower by 10% in the non-invasive weaning arm (vs. the inva-
sive arm), the INMB fell by > 90% from £10,838 to 603, and 
the expected probability of long-term cost effectiveness fell 
to around 79% (Table 8 and Fig. 8 in the ESM). If future 
survival estimates reflect patterns shown here (Fig. 1 in the 
ESM), and future patient costs accumulate based on patterns 
observed during the trial, without improvements in QALYs 
(Table 8 in the ESM, scenario 4), NIV is no longer be cost 
effective (change from INMB of £10,838 in favour of NIV 
to INMB of £6061 favouring invasive weaning).
4  Discussion
This trial-based economic evaluation showed that NIV 
has potential to be cost effective compared with invasive 
weaning; the probability of cost effectiveness ranged from 
57 to 59%, depending on the cost-effectiveness threshold. 
This is likely to be largely driven by the difference in the 
mean ± standard error number of days in the ICU (14 ± 1.08 
vs. 15 ± 1.12) and ICU-related costs (Table 1; Table 1 and 
9 in the ESM).
This finding remained robust to most sensitivity and sub-
group analyses considered. The main exception related to 
subgroups of patients without COPD and those who required 
surgery, in whom IMV was the dominant strategy.
The primary clinical endpoint of time to liberation from 
mechanical ventilation did not show a statistical difference: 
median 4.3 vs. 4.5 days; adjusted hazard ratio 1.1; 95% CI 
0.89–1.40. However, a lack of difference in the time to liber-
ation from ventilation does not imply that costs of ICU care 
beyond this point are no longer relevant for the purposes of 
cost effectiveness. In this cost-effectiveness analysis, health 
Fig. 2  Sensitivity analyses and subgroup results (cost-effectiveness threshold of £30,000/quality-adjusted life-year)
 I. Khan et al.
resource use and HRQoL beyond liberation from ventilation 
were considered, which could logically result in differing 
conclusions. We observed that, on average, patients in the 
invasive group stayed about 1 day long in the ICU than those 
in the non-invasive group (Table 1 in the ESM). Moreo-
ver, other costs, including broader NHS and broader soci-
etal costs, also influenced the observed cost differential in 
favour of NIV. In addition, improved QALYs associated with 
NIV were observed once deaths are accounted for (driven 
by more deaths in the IMV arm). The cost-effectiveness 
analysis considered a broader assessment of consequences 
than the clinical study, resulting in a conclusion that NIV 
weaning may be cost effective, particularly for patients with 
COPD.
The differences in costs and QALYs between the trial 
comparators were not statistically significant. However, 
the trial was not powered to detect such differences over a 
short-term time horizon. A power calculation for a future 
trial covering a 5-year follow-up period, using the observed 
results from this trial, taking into account long-term survival 
predictions (i.e. using mean costs and projected QALYs and 
their standard deviations along with a £30,000 cost-effec-
tiveness threshold), would require a sample size of at least 
215 per group (430 in total) to show with at least 80% power 
(5% significance) that the INMB would be > 0. This would 
be the case even if NIV weaning was more expensive by 
as much as £2737 (one possible scenario of the sensitivity 
analyses in Table 8 in the ESM). Hence, this trial provides 
useful data to prospectively design a future (larger) con-
firmatory trial with longer follow-up that could demonstrate 
long-term cost effectiveness. In the more optimistic sce-
nario, where NIV was projected over 5 years to be cheaper 
by £302 (Table 2; Table 8 in the ESM), the sample size 
required would be around 120 per group (240 in total). The 
observed probabilities of cost effectiveness observed in this 
trial, although < 80%, may partly be because the sample size 
(n = 364 vs. n = 430) was smaller than required to demon-
strate cost effectiveness [36].
Previous clinical trials have reported significant clinical 
benefits with the NIV protocol among patients with COPD, 
in contrast to studies that enrolled mixed populations [3]. 
However, none of those studies reported impacts on HRQoL 
among survivors. Therefore, our findings add new insights 
into available evidence, emphasising that other factors may 
need to be considered when deciding on optimal weaning 
approaches for patients in critical care settings who present 
without COPD.
When the benefits of NIV weaning on mortality were 
extrapolated to 5 years, the NIV protocol remained cost 
effective (5-year ICER £4618/QALY (INMB £6568 at a 
cost-effectiveness threshold of £20,000) with probability of 
cost effectiveness of NIV > 90%). NIV as a bridge to libera-
tion from mechanical ventilation could be recommended on 
economic grounds provided that the assumptions of constant 
costs and health utilities beyond the trial period continue to 
hold in practice. The longer-term cost effectiveness of NIV 
is highly dependent on assumptions surrounding costs and 
benefits beyond 6 months. However, we have included sen-
sitivity analyses for various parameters (including survival 
rates) while noting that estimated survival rates were broadly 
similar to those reported in the literature [33–35]. We also 
suggest that additional information on longer-term outcomes 
is needed in future studies to reduce the uncertainty around 
our estimates.
To our knowledge, this is the first trial-based economic 
evaluation that compares the cost effectiveness of two pro-
tocolised weaning strategies for patients in the ICU. Previ-
ous studies have compared the cost effectiveness of NIV 
weaning with other strategies and in different countries and 
clinical settings. Chandra et al. [7] conducted a cost-effec-
tiveness analysis of multiple interventions for COPD, includ-
ing a comparative assessment of weaning protocols (NIV 
vs. weaning with invasive ventilation), within the Canadian 
setting, using a Markov probabilistic model. The results 
indicated that weaning with NIV dominated weaning with 
invasive ventilation; the probability of cost effectiveness for 
NIV weaning exceeded 99% at cost-effectiveness thresholds 
as low as $25,000 per QALY gained. Nonetheless, the analy-
sis was restricted to patients with COPD. We also considered 
using the data from Chandra et al. [7] as an external input 
but felt that long-term extrapolations of survival could be 
misleading or unreliable because the populations differed. 
Other studies reported costs associated with NIV weaning 
in critical care settings [5, 6] but did not report HRQoL 
outcomes and were either based on small sample sizes [6] or 
focussed solely on patients with a COPD exacerbation [37].
A strength of the Breathe trial was that it was prospec-
tively designed for an economic evaluation using individual-
level data. Costs and outcomes were carefully considered 
in the trial design with a view to reaching a robust cost-
effectiveness conclusion based on a large sample. How-
ever, potential limitations to this analysis do exist. First, we 
assumed that the baseline utility value for each patient was 
− 0.402, the value assigned by the UK EQ-5D-3L tariff to 
an unconscious health state. This assumption is in keeping 
with broader methodological practice for trial-based eco-
nomic evaluations conducted in critical care settings [38]. 
Moreover, we recently demonstrated that applying alterna-
tive fixed baseline utility scores generally had no effect on 
incremental QALY calculations [38]. Second, approximately 
35% of QALY data and 6–40% of costs (at the component 
level) were missing by 6 months. Had our base-case cost-
effectiveness analysis only considered individuals with com-
plete QALY and cost data, we would have removed approxi-
mately 50% of patients from the analysis, which would have 
likely biased the results. After demonstrating that the data 
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were missing at random, we used multiple imputation to 
‘replace’ missing values to allow a comprehensive analy-
sis using the whole dataset. Third, the modelling under-
taken was constrained by assumptions concerning post-
6-month costs and health utilities. However, a systematic 
search of external studies that compared these two weaning 
approaches revealed that none reported long-term economic 
outcomes. As a result, the evidence base for extrapolating 
cost effectiveness is currently weak. Longer follow-up would 
have reduced uncertainty surrounding our long-term cost-
effectiveness estimates.
5  Conclusions
The results from the Breathe study indicated that early extu-
bation to NIV did not shorten time to liberation from any 
ventilation. The probability of NIV being cost effective rela-
tive to weaning without NIV ranged between 57 and 59% 
and was higher for patients with COPD (82–87%). Future 
trials with extended follow-up are needed to reduce uncer-
tainty surrounding the long-term cost effectiveness of NIV.
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